Rationalizing Effective Phase 1 Trial Design for Combination Therapies: Combining Mesothelin-Specific CAR-T (huCART-meso) Cells with Oncolytic Virus VCN-01
Time: 10:00 am day: Focus Day Track 1
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok